• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cymabay Therapeutics (NQ: CBAY )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cymabay Therapeutics

< Previous 1 2 3 4 Next >
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production
March 15, 2024
Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology. Anticipating a... 
Via Benzinga
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
March 14, 2024
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
February 13, 2024
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800... 
Via Benzinga
Fear & Greed Index Remains In 'Extreme Greed' Zone Ahead Of Inflation Data; Dow Hits Record high
February 13, 2024
The CNN Money Fear and Greed index remained in the "Extreme Greed" zone on Monday. U.S. stocks closed mixed on Monday, with the Dow Jones index climbing to a fresh high during the session. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
6 Analysts Have This to Say About CymaBay Therapeutics
December 15, 2023
Via Benzinga
Recap: CymaBay Therapeutics Q3 Earnings
November 07, 2023
Via Benzinga
Dow Up Triple Digits, Hits Fresh Highs
February 12, 2024
Stocks are on the rise today, as investors towards tomorrow's inflation data. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Why is CymaBay (CBAY) Stock Up 25% Today?
February 12, 2024
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences. 
Via InvestorPlace
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday
February 12, 2024
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
Exposures US Equities
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
February 12, 2024
Via Benzinga
Earnings Outlook For CymaBay Therapeutics
November 06, 2023
Via Benzinga
Where CymaBay Therapeutics Stands With Analysts
November 06, 2023
Via Benzinga
Why CymaBay Therapeutics Stock Is Sinking This Week
September 21, 2023
The stock has given up some of its gains but remains up more than 130% year to date. 
Via The Motley Fool
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue... 
Via Benzinga
Exposures Product Safety
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
February 12, 2024
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment. 
Via Investor's Business Daily
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
December 28, 2023
The company is working on the first treatment that could make a difference in the itching associated with a liver disease. 
Via Investor's Business Daily
Raymond James Maintains Strong Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
November 08, 2023
Via Benzinga
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today
October 23, 2023
It became increasingly likely that seladelpar will ultimately gain regulatory approval. 
Via The Motley Fool
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game. 
Via InvestorPlace
UBS Maintains Buy Rating for CymaBay Therapeutics: Here's What You Need To Know
September 26, 2023
Via Benzinga
Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease
September 21, 2023
Thursday, CymaBay Therapeutics Inc (NASDAQ: CBAY) initiated the AFFIRM Phase 3b/4 confirmatory study to evaluate the effect of seladelpar on clinical outcomes in patients with compensated cirrhosis due... 
Via Benzinga
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
September 12, 2023
The company is about to reap more money than previously expected from a new capital-raising effort. 
Via The Motley Fool
Why CymaBay Therapeutics Stock Popped Again Today
September 11, 2023
Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising. 
Via The Motley Fool
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 08, 2023
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics. 
Via Benzinga
Why CymaBay Therapeutics Stock Is Jumping Today
September 08, 2023
The momentum continues after CymaBay reported great clinical results on Thursday. 
Via The Motley Fool
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
September 08, 2023
The company is working on a treatment for a liver disease that can cause severe itching. 
Via Investor's Business Daily
Smartsheet, Kroger, Lantronix And Other Big Stocks Moving Higher On Friday
September 08, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. Lantronix, Inc. (NASDAQ: LTRX) shares jumped 26.3% to... 
Via Benzinga
Topics Stocks
Exposures US Equities
CymaBay Therapeutics' Lead Drug Candidate Hits Main Goal In Pivotal Study For Liver Damage
September 07, 2023
CymaBay Therapeutics Inc (NASDAQ: CBAY) released topline results from its Phase 3 pivotal RESPONSE study of seladelpar for adult patients with  
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
September 07, 2023
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap